Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

Company Overview - Allogene Therapeutics is a clinical-stage biotechnology company based in South San Francisco, focusing on the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune diseases [4] - The company aims to create a pipeline of "off-the-shelf" CAR T cell product candidates to provide readily available cell therapy on-demand, more reliably, and at greater scale to more patients [4] Upcoming Financial Results - Allogene Therapeutics will report its fourth quarter and full year 2025 financial results on March 12, 2026, after the market closes [1] - A live audio webcast and conference call will follow the announcement at 2:00 p.m. PT/5:00 p.m. ET [1] Webcast and Conference Call Details - The listen-only webcast will be accessible on the company's website under the Investors tab in the News and Events section, with a replay available for approximately 30 days [2] - Registration is required for those who wish to ask questions during the conference call, and participants will receive a personal PIN upon registration [3]